Alina Markova MD

Dermatology•New York, NY

Associate Attending, Clinical Director of Dermatology Service

Request Appointment

530 East 74th StreetNew York, NY 10021
Book by Phone+1(231) 680-2491

Education & Training

Boston University Medical CenterResidency, Dermatology, 2013 - 2016
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2012 - 2013
The Warren Alpert Medical School of Brown UniversityClass of 2012, MD
Johns Hopkins UniversityBA, Mathematics, 2004 - 2008

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2022 - 2027
CT State Medical License 2025 - 2026
NY State Medical License 2016 - 2025
MA State Medical License 2012 - 2016
American Board of Dermatology Dermatology

Clinical Trials

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease Start of enrollment: 2019 May 14
Completed
Phase 2
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Start of enrollment: 2020 Sep 16
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer Start of enrollment: 2021 Dec 15
COMPLETED
PHASE2
Roles: Contact, Principal Investigator
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant Start of enrollment: 2022 Dec 22
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors Start of enrollment: 2023 Mar 10
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields Start of enrollment: 2020 Jul 09
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Histopathologic and Clinical Characteristics of Cutaneous Toxicities of Tyrosine Kinase Inhibitors: Insights Into Pathologic Mechanisms From a Retrospective Cohort.
Ian Nykaza, Tania Platero-Portillo, Ellin Berman, Mark B Geyer, Jae H Park
The American Journal of Dermatopathology. 2025-09-08
Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.
Ian Nykaza, Andrea Moy, Stephen W Dusza, Alison Moskowitz, Gopa Iyer
The Oncologist. 2025-09-01
Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.
Ian Nykaza, Stephen W Dusza, Jonathan E Rosenberg, Gopa Iyer, Emily Feld
JAMA Dermatology. 2025-09-01

Lectures

Dermatological Emergencies: The Skin As A Sentinal
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Press Mentions

Q&A with Director of the NIH Dermatology Consultation ServiceDecember 24th, 2024
Are Nail Salon UV Lamps a Skin Cancer Risk?April 30th, 2014
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerFebruary 13th, 2024